Omnicell (NASDAQ:OMCL – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its peers? We will compare Omnicell to similar businesses based on the strength of its dividends, earnings, risk, profitability, valuation, institutional ownership and analyst recommendations.
Risk and Volatility
Omnicell has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Omnicell’s peers have a beta of 2.57, indicating that their average share price is 157% more volatile than the S&P 500.
Profitability
This table compares Omnicell and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Omnicell | 3.59% | 5.69% | 3.61% |
| Omnicell Competitors | -304.51% | -178.77% | -22.17% |
Valuation and Earnings
This table compares Omnicell and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Omnicell | $1.24 billion | $2.05 million | 38.90 |
| Omnicell Competitors | $1.89 billion | $135.83 million | 10.98 |
Omnicell’s peers have higher revenue and earnings than Omnicell. Omnicell is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Insider and Institutional Ownership
97.7% of Omnicell shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of current recommendations for Omnicell and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Omnicell | 0 | 1 | 7 | 1 | 3.00 |
| Omnicell Competitors | 4280 | 10554 | 18334 | 829 | 2.46 |
Omnicell currently has a consensus price target of $57.86, suggesting a potential upside of 54.95%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.11%. Given Omnicell’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Omnicell is more favorable than its peers.
Summary
Omnicell beats its peers on 9 of the 13 factors compared.
Omnicell Company Profile
Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.
